sarecycline (Rx)

Brand and Other Names:Seysara
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 60mg
  • 100mg
  • 150mg

Acne Vulgaris

Indicated for treatment of inflammatory lesions of non-nodular moderate-to-severe acne

<54 kg: 60 mg PO qDay

55-84 kg: 100 mg PO qDay

85-136 kg: 150 mg PO qDay

If improvement after 12 weeks not observed, reassess treatment

Dosing Considerations

Limitations of use

  • Efficacy beyond 12 weeks and safety beyond 12 months not established
  • Not evaluated for treatment of infections
  • To reduce development of drug-resistant bacteria and maintain effectiveness of other antibacterial drugs, used only as indicated

Dosage Forms & Strengths

tablet

  • 60mg
  • 100mg
  • 150mg

Acne Vulgaris

Indicated for treatment of inflammatory lesions of non-nodular moderate-to-severe acne in patients aged ≥9 yr

<9 years: Safety and efficacy not established

≥9 years

  • 33-54 kg: 60 mg PO qDay
  • 55-84 kg: 100 mg PO qDay
  • 85-136 kg: 150 mg PO qDay
  • If improvement after 12 weeks not observed, reassess treatment

Dosing Considerations

Limitations of use

  • Efficacy beyond 12 weeks and safety beyond 12 months not established
  • Not evaluated for treatment of infections
  • To reduce development of drug-resistant bacteria and maintain effectiveness of other antibacterial drugs, used only as indicated
Next:

Interactions

Interaction Checker

and sarecycline

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            1-10%

            Nausea (3.1%)

            <1%

            Vulvovaginal mycotic infection

            Vulvovaginal candidiasis

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity to any tetracyclines

            Cautions

            Clostridium difficile-associated diarrhea (CDAD) reported with use of nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, consider discontinuing ongoing antibacterial drug use not directed against C difficile and initiating treatment-appropriate measures

            Central nervous system side effects including light-headedness, dizziness or vertigo reported with tetracycline use; patients who experience symptoms should be cautioned about driving vehicles or using hazardous machinery; symptoms may disappear during therapy and may disappear when drug is discontinued

            Photosensitivity manifested by an exaggerated sunburn reaction observed with tetracyclines; instruct patients to minimize or avoid exposure to natural or artificial sunlight; if patients need to be outdoors while on therapy, they should wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician

            Bacterial resistance to tetracyclines may develop; because of this, use only as indicated

            As with other antibiotics, use may result in overgrowth of nonsusceptible organisms, including fungi; if superinfection occurs, discontinue therapy and institute appropriate therapy

            Intracranial hypertension

            • Intracranial hypertension in adults and adolescents associated with tetracycline use; clinical manifestations include headache, blurred vision, and papilledema; if visual disturbance occurs during treatment, patients should be checked for papilledema
            • Women of childbearing age who are overweight have a greater risk for developing intracranial hypertension
            • Patients should be questioned for visual disturbances prior to initiation of treatment with tetracyclines
            • Concomitant use of isotretinoin should be avoided because isotretinoin, a systemic retinoid, is also known to cause intracranial hypertension

            Teratogenic effects

            • Can cause fetal harm if used during pregnancy
            • Use during tooth and bone development
              • Use during tooth development (last half of pregnancy, infancy, and childhood to age 8 years) may cause permanent discoloration of the teeth (yellow-grey-brown); enamel hypoplasia reported with tetracyclines; advise patient of potential risk
              • May cause reversible inhibition of bone growth during pregnancy, infancy, and early childhood
              • All tetracyclines form a stable calcium complex in any bone-forming tissue
              • Decreased fibula growth rate observed in premature infants given PO tetracycline in doses of 25 mg/kg q6hr; reversible when drug discontinued
              • Also see Pregnancy

            Drug interaction overview

            • Avoid coadministration with oral retinoids; may have additive effects on increasing intracranial pressure
            • Coadministration with antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations decrease tetracycline absorption, which may decrease efficacy; separate doses
            • May interfere with bacteriocidal action of penicillin; avoid coadministration
            • May depress plasma prothrombin activity, which may increase bleeding risk in patients who are on anticoagulant therapy
            • May increase serum concentration of P-gp substrates; monitor for toxicities if P-gp substrates coadministered
            Previous
            Next:

            Pregnancy

            Pregnancy

            Like other tetracycline-class antibacterial drugs, may cause discoloration of deciduous teeth and reversible inhibition of bone growth when administered during second and third trimesters of pregnancy

            Pregnant women should discontinue sarecycline as soon as pregnancy is recognized

            Animal data

            • Crosses placenta and is found in fetal plasma; sarecycline induced skeletal malformations in fetuses when administered PO to pregnant rats during the period of organogenesis at a dose 1.4 times the maximum recommended human dose (MRHD) of 150 mg/day (based on AUC comparison)

            Infertility

            • Based on animal studies, can lead to impaired spermiation and sperm maturation, resulting in abnormal sperm morphology and poor motility
            • Avoid use in males who are attempting to conceive a child

            Lactation

            Tetracyclines are excreted in human milk

            Because of the potential for serious adverse reactions on bone and tooth development in nursing infants, sarecycline is not recommended in breastfeeding women

            Animal studies

            • When dosing with sarecycline continued through the period of lactation, decreases in offspring survival, offspring body weight, and implantation sites and viable embryos in offspring females occurred at a dose 3 times the MRHD

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Tetracycline-derived antibiotic; narrow spectrum of activity targeting acne-specific pathogens (ie, Propionibacterium acnes, Staphylococcus aureus)

            Elicits limited activity against aerobic gram-negative gastrointestinal organisms compared with minocycline and doxycycline

            Absorption

            Peak plasma time: 1.5-2 hr

            Effect of high-fat and high-calorie meal

            • Peak plasma time: Delayed by ~0.53 hr
            • Peak plasma concentration: Decreased by 31%
            • AUC: Decreased by 27%

            Distribution

            Protein bound: 62.5-74.7%

            Vd: 91.4-97 L

            Metabolism

            Minimal hepatic metabolism (<15%)

            Minor metabolites resulting from nonenzymic epimerization, O-/N-demethylation, hydroxylation, and desaturation found

            Elimination

            Half-life: 21-22 hr

            Clearance: 3 L/hr

            Excretion: 42.6% feces (14.9% unchanged); 44.1% urine (24.7% unchanged)

            Previous
            Next:

            Administration

            Oral Administration

            Take with or without food

            Swallow with adequate amounts of fluid to reduce risk of esophageal irritation or ulceration

            Storage

            Store at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F)

            Protect from moisture and excessive heat

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.